TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02470234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl ER Capsules, 10 mg
Description: Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl ER Capsules, 15 mg
Description: Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl ER Capsules, 20 mg
Description: Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
Study: NCT03217487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal epithelial autograft
Description: Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal conjunctival autograft
Description: A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diamond knife
Description: A diamond knife to create a particular shaped limbal graft for transplantation
Study: NCT03182088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine infusion (0.025 mcg/Kg/min)
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine infusion (0.050 mcg/Kg/min)
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine infusion (0.075 mcg/Kg/min)
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The patient will receive spinal anesthesia using Bupivacaine (10 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The patient will receive spinal anesthesia using Bupivacaine (10 mg).
Study: NCT03100240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Supper Long Protocol
Description: In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
Study: NCT03182088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The patient will receive spinal anesthesia using Bupivacaine (10 mg).
Study: NCT04488900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Capsule
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo
Study: NCT04785014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional
Description: In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
Study: NCT02567370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04785014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional
Description: In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
Study: NCT02790398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic treatment protocol
Description: Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic treatment protocol + PA regulation component
Description: Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
Study: NCT01457170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline (Placebo)
Description: During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline (Placebo)
Description: During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
Study: NCT03380546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial insulin
Description: Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
Study: NCT04288453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in a 8-week community-based activity program
Description: Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation
Study: NCT02563535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB
Description: angioplasty with Litos drug eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: angioplasty with conventional balloon
Study: NCT01689012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Exercise
Study: NCT02916888

Intervention type: OTHER
Intervention: Care provided by general pediatrician
Description: Standard of care management of atopic dermatitis by a general pediatrician.

Intervention type: OTHER
Intervention: Care provided by pediatric dermatologist
Description: Standard of care management of atopic dermatitis by a pediatric dermatologist.
Study: NCT03729258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infex 400 MR
Description: Infex (cefpodoxime) 400mg once a day (QD) for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infex 200 IR
Description: Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
Study: NCT01505673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo injection of 1.8mg saline once daily for 6-months
Study: NCT04613557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYAD-211
Description: Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxan
Description: Preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: Preconditioning chemotherapy
Study: NCT00978055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Liothyronine Sodium Tablets
Description: Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Study: NCT01709591

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal education
Study: NCT02289040

Intervention type: PROCEDURE
Intervention: cardiac surgery
Description: cardiac surgery with extracorporeal circulation for congenital heart disease
Study: NCT03592199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
Study: NCT02384408

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endometrial Biopsy
Description: Histological assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Histological assessment
Study: NCT00978055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2: Cytomel® Tablets
Description: Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Study: NCT04686851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment and follow-up
Description: All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA.
Study: NCT02384408

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transvaginal Ultrasound
Description: Endometrial Thickness made by ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound
Description: Endometrial Thickness made by ultrasound

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endometrial Immunohistochemical
Description: Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
Study: NCT04615416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Training via Telehealth
Description: The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
Study: NCT01558544

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery to remove ovaries or high dose chemotherapy
Description: oophorectomy to remove a disease ovary.
Study: NCT02384408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Immunohistochemical
Description: Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
Study: NCT03421119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 MG/ML Pen Injector
Description: Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML Pen Injector
Description: Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea/non-sulfonylurea insulin secretagogues
Description: Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea/non-sulfonylurea insulin secretagogues
Description: Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
Study: NCT00656110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml
Description: Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline - 1ml
Description: Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
Study: NCT01368783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: 400 mg/day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir(ATZ) and Tenofovir(TDF)
Description: ATZ 400 mg with TDF/day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir(ATZ) + Ritonavir
Description: ATZ 300 mg + Ritonavir 100 mg/day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir(ATZ) + tenofovir(TDF) + ritonavir
Description: ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
Study: NCT02657681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham
Description: A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
Study: NCT00616382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
Study: NCT00006164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + Ribavirin
Description: Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a + Ribavirin
Description: Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 90 mcg/week injection, for 3.5 years
Study: NCT02947178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial iliac regional soft tissue infiltration blockade
Description: Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial iliac regional soft tissue infiltration blockade
Description: Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Score Survey
Description: Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Score Survey
Description: Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pill Count
Description: Patient reported as needed (prn) pain medication usage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pill Count
Description: Patient reported as needed (prn) pain medication usage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Study: NCT03928938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic patient reported outcomes
Description: Electronic patient reported outcomes-tool
Study: NCT02591667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront staging laparoscopy + peritoneal biopsy
Description: Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab
Description: Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical re-exploration
Description: Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
Study: NCT02204605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Consensus Opinion